Genetic Polymorphisms Contribute to the Individual Variations of Imatinib Mesylate Plasma Levels and Adverse Reactions in Chinese GIST Patients

Imatinib mesylate (IM) has dramatically improved the outcomes of gastrointestinal stromal tumor (GIST) patients. However, the clinical responses of IM may considerably vary among single individuals. This study aimed to investigate the influences of genetic polymorphisms of drug-metabolizing enzyme (...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jing, Chen, Zhiyu, Chen, Hanmei, Hou, Yingyong, Lu, Weiqi, He, Junyi, Tong, Hanxing, Zhou, Yuhong, Cai, Weimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372619/
https://www.ncbi.nlm.nih.gov/pubmed/28335376
http://dx.doi.org/10.3390/ijms18030603

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372619/
https://www.ncbi.nlm.nih.gov/pubmed/28335376
http://dx.doi.org/10.3390/ijms18030603

Ejemplares similares